Clinical trials offer great challenges to those who accept the daunting odds of success but they do so knowing that successful outcomes will have extensive benefits, first and foremost to patients impacted by the condition in question but also to society, financial stakeholders and to the careers of those who navigate a course through the challenges. Addressing these challenges via use of high quality tools is critical to successful completion of a clinical trial.
This webinar will focus on specific analytical test solutions offered by ICON Central Laboratory for Type II Diabetes that enable the creation of high quality laboratory data sets which in turn enable an accurate and efficient assessment of the test compound. It will focus on solutions which address clinical trial challenges including global laboratory harmonisation, accurately defining clinical status via laboratory endpoints, longitudinal trending of subjects and management of analyte stability and analytical interference. It is the belief of ICON Central Laboratories that these considered solutions will provide high quality options that will increase the opportunity for success for those undertaking the challenge posed by drug development.
Andrew Roche, Ph.D., Scientific Director, Global Validation, Scientific Affairs, ICON
Andrew, a PhD with in depth knowledge of the intricacies of analytical methods and their applications within clinical trials, oversees the Scientific Affairs and Global Validations functions of ICL.
Andrew has over 15 years’ experience in the clinical trial industry. He began his career within the infectious disease arena of biotech where he successfully led projects designed to identify and validate large molecule drug targets within pathogenic microorganisms. Andrew then moved into the field of biomarkers and led projects that created marketed immunoassay products for the detection of novel biomarkers of organ toxicity. Prior to joining ICON Andrew co-founded a bioanalytical CRO dedicated to the development, validation and utilization of customised methods for the quantification of large molecule drugs, anti-drug antibodies and biomarkers.
Andrew holds a B.A. Mod, and Ph.D. in Medical Microbiology from Trinity College Dublin and has authored several scientific publications. In his current role as Scientific Director he focuses on the intricacies of analytical methods and their applications within clinical trials with the goal of facilitating the creation of an accurate and precise analytical data set thereby facilitating an accurate clinical assessment of analytical data.
Martin Benson, Ph.D., Senior Director and Global Lead, Cardiometabolic Drug Development Services
Dr. Benson is a highly knowledgeable cardiometabolic pharmacologist with over 36 years of experience. Dr. Benson has experience working internationally in preclinical research and early clinical development in blue-chip pharmaceutical companies. He gained his PhD in Pharmacology/Biochemistry at the Royal Veterinary College, University of London.
Who Should Attend?
Senior professionals from biopharmaceutical companies working within clinical research
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 89 locations in 37 countries and has approximately 12,200 employees.